Up-regulated HMGB1 in the pleural effusion of non-small cell lung cancer (NSCLC) patients reduces the chemosensitivity of NSCLC cells

Abstract

Background:

Pleural effusion is one of the complications of human non-small cell lung cancer (NSCLC). High mobility group box-1 protein (HMGB1) correlates highly with invasion and metastasis in multiple tumors. The aim of this study was to explore the clinical value of HMGB1 in NSCLC patients, and to investigate the role of HMGB1 in the development of pleural effusion. In addition, we also investigated the regulatory role of HMGB1 in the sensitivity of NSCLC cells to cisplatin.

Methods:

46 NSCLC malignant pleural effusion (MPE) and 31 benign pleural effusion samples were quantitatively analyzed with Enzyme-Linked Immunosorbent Assay (ELISA) for cytokines, such as IL-1beta, IL-6, IL-8 and HMGB1. The HMGB1 expression in NSCLC tissues was examined with RT-qPCR and western blotting methods. Then the influence by HMGB1 on the chemosensitivity of lung cancer A549 cells was examined with MTT assay and colony forming assay for the A549 cells post the treatment with cisplatin or (and) HMGB1.

Results:

The results demonstrated that HMGB1 was up-regulated in the pleural effusion of NSCLC patients, along with the up-regulated levels of proinflammatory cytokines such as IL-6 and IL-8. And the up-regulation of HMGB1 was confirmed at both the mRNA and protein levels in the NSCLC tissues. Recombinant HMGB1 reduced the sensitivity of A549 cells to cisplatin in vitro.

Conclusions:

In conclusion, HMGB1 was up-regulated in the pleural effusion and tumor tissues of NSCLC patients. HMGB1 reduced the sensitivity of NSCLC A549 cells to cisplatin in vitro.

Keywords

Chemosensitivity Cisplatin High mobility group box-1 protein (HMGB1)Non-small cell lung cancer (NSCLC)

Get full access to this article

View all access options for this article.

References

Feng

Yin

. The effect of HMGB1 on the clinicopathological and prognostic features of non-small cell lung cancer. Oncotarget. 2016;7(15):20507-20519.

DeSantis

Lin

Mariotto

et al . Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64(4):252-271.

Shen

Pouliot

Hall

Gottesman

. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev. 2012;64(3): 706-721.

Lotze

Tracey

. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005;5(4):331-342.

Thomas

Stott

. H1 and HMGB1: modulators of chromatin structure. Biochem Soc Trans. 2012;40(2):341-346.

Yang

Tracey

. Targeting HMGB1 in inflammation. Biochim Biophys Acta. 2010;1799:149-156.

Pribis

Al-Abed

Yang

et al . The HIV protease inhibitor saquinavir inhibits HMGB1 driven inflammation by targeting the interaction of cathepsin V with TLR4/MyD88. Mol Med. 2015;21(1):1.

Bustin

. Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol. 1999;19(8):5237-5246.

Weng

Deng

Xie

Liu

Gong

. Expression and significance of HMGB1, TLR4 and NF-κB p65 in human epidermal tumors. BMC Cancer. 2013;13(1):311.

10.

Zhang

Wang

. Expression of HMGB1 and NF-κB p65 and its significance in non-small cell lung cancer. Contemp Oncol (Pozn). 2013;17(4):350-355.

11.

Kew

Penzo

Habiel

Marcu

. The IKKα-dependent NF-κB p52/RelB noncanonical pathway is essential to sustain a CXCL12 autocrine loop in cells migrating in response to HMGB1. J Immunol. 2012;188(5):2380-2386.

12.

Fiuza

Bustin

Talwar

et al . Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood. 2003;101(7):2652-2660.

13.

Wang

Ding

Zheng

Wang

. MiR-1244 sensitizes the resistance of non-small cell lung cancer A549 cell to cisplatin. Cancer Cell Int. 2016;16(1):30.

14.

Xiao

Liu

. MiR-1423p functions as a potential tumor suppressor directly targeting HMGB1 in non-small-cell lung carcinoma. Int J Clin Exp Pathol. 2015;8(9):10800-10807.

15.

Bible

Kaufmann

. Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res. 1996;56(21):4856-4861.

16.

Jakubowska

Naumnik

Niklińska

Chyczewska

. Clinical significance of HMGB-1 and TGF-β level in serum and BALF of advanced non-small cell lung cancer. Adv Exp Med Biol. 2015; 852:49-58.

17.

Zhang

Wang

. Expression of HMGB1 and NF-κB p65 and its significance in non-small cell lung cancer. Contemp Oncol (Pozn). 2013;17(4):350-355.

18.

Shang

Jia

Tian

et al . Serum high mobility group box protein 1 as a clinical marker for non-small cell lung cancer. Respir Med. 2009;103(12):1949-1953.

19.

Zhu

Luo

et al . HMGB1 induces human non-small cell lung cancer cell motility by activating integrin αvβ3/FAK through TLR4/NF-κB signaling pathway. Biochem Biophys Res Commun. 2016;480(4):522-527.

20.

Feng

Yin

. The effect of HMGB1 on the clinicopathological and prognostic features of non-small cell lung cancer. Oncotarget. 2016;7(15):20507-20519.

21.

Hammerman

Lawrence

Voet

et al . Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489(7417):519-525.

22.

Collisson

Campbell

Brooks

et al . Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511(7511):543-550.

23.

Judson

Kelland

. New developments and approaches in the platinum arena. Drugs. 2000;59(Suppl 4):29-36, discussion 37-38.

24.

Rosell

Lord

Taron

Reguart

. DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer. 2002;38(3):217-227.